JP2004509895A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509895A5
JP2004509895A5 JP2002529112A JP2002529112A JP2004509895A5 JP 2004509895 A5 JP2004509895 A5 JP 2004509895A5 JP 2002529112 A JP2002529112 A JP 2002529112A JP 2002529112 A JP2002529112 A JP 2002529112A JP 2004509895 A5 JP2004509895 A5 JP 2004509895A5
Authority
JP
Japan
Prior art keywords
epoxy
isoindole
methyl
dioxo
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002529112A
Other languages
English (en)
Japanese (ja)
Other versions
JP4966477B2 (ja
JP2004509895A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/019655 external-priority patent/WO2002024702A1/en
Publication of JP2004509895A publication Critical patent/JP2004509895A/ja
Publication of JP2004509895A5 publication Critical patent/JP2004509895A5/ja
Application granted granted Critical
Publication of JP4966477B2 publication Critical patent/JP4966477B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002529112A 2000-09-19 2001-06-20 核ホルモン・レセプタ機能のモジュレーターである、縮合複素環式スクシンイミド化合物およびその類縁体 Expired - Fee Related JP4966477B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23351900P 2000-09-19 2000-09-19
US60/233,519 2000-09-19
US28443801P 2001-04-18 2001-04-18
US28473001P 2001-04-18 2001-04-18
US60/284,438 2001-04-18
US60/284,730 2001-04-18
PCT/US2001/019655 WO2002024702A1 (en) 2000-09-19 2001-06-20 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Publications (3)

Publication Number Publication Date
JP2004509895A JP2004509895A (ja) 2004-04-02
JP2004509895A5 true JP2004509895A5 (cg-RX-API-DMAC7.html) 2008-08-21
JP4966477B2 JP4966477B2 (ja) 2012-07-04

Family

ID=27398441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002529112A Expired - Fee Related JP4966477B2 (ja) 2000-09-19 2001-06-20 核ホルモン・レセプタ機能のモジュレーターである、縮合複素環式スクシンイミド化合物およびその類縁体

Country Status (36)

Country Link
US (1) US20040176324A1 (cg-RX-API-DMAC7.html)
EP (1) EP1319007B9 (cg-RX-API-DMAC7.html)
JP (1) JP4966477B2 (cg-RX-API-DMAC7.html)
KR (1) KR100765670B1 (cg-RX-API-DMAC7.html)
CN (2) CN1995039A (cg-RX-API-DMAC7.html)
AR (1) AR035340A1 (cg-RX-API-DMAC7.html)
AT (1) ATE318822T1 (cg-RX-API-DMAC7.html)
AU (2) AU6994301A (cg-RX-API-DMAC7.html)
BG (1) BG107675A (cg-RX-API-DMAC7.html)
BR (1) BR0113980A (cg-RX-API-DMAC7.html)
CA (1) CA2423071A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2003780A3 (cg-RX-API-DMAC7.html)
DE (1) DE60117551T2 (cg-RX-API-DMAC7.html)
DK (1) DK1319007T3 (cg-RX-API-DMAC7.html)
EE (1) EE200300108A (cg-RX-API-DMAC7.html)
ES (1) ES2260244T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20074144B (cg-RX-API-DMAC7.html)
HK (1) HK1054230B (cg-RX-API-DMAC7.html)
HR (1) HRP20030305B9 (cg-RX-API-DMAC7.html)
HU (1) HUP0400455A3 (cg-RX-API-DMAC7.html)
IL (1) IL155019A0 (cg-RX-API-DMAC7.html)
IS (1) IS6750A (cg-RX-API-DMAC7.html)
MX (1) MXPA03002412A (cg-RX-API-DMAC7.html)
MY (1) MY138531A (cg-RX-API-DMAC7.html)
NO (1) NO329931B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ524803A (cg-RX-API-DMAC7.html)
PE (1) PE20020729A1 (cg-RX-API-DMAC7.html)
PL (1) PL361707A1 (cg-RX-API-DMAC7.html)
PT (1) PT1319007E (cg-RX-API-DMAC7.html)
SK (1) SK4982003A3 (cg-RX-API-DMAC7.html)
TW (1) TWI305208B (cg-RX-API-DMAC7.html)
UA (1) UA78686C2 (cg-RX-API-DMAC7.html)
UY (1) UY26808A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002024702A1 (cg-RX-API-DMAC7.html)
YU (1) YU20003A (cg-RX-API-DMAC7.html)
ZA (1) ZA200302963B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
EP1553074B1 (en) 2002-08-12 2014-06-18 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
WO2004110978A2 (en) * 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
US7417040B2 (en) * 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
WO2007015567A1 (ja) * 2005-08-01 2007-02-08 Takeda Pharmaceutical Company Limited 環状アミン化合物
US20100004249A1 (en) * 2006-07-11 2010-01-07 Takahiro Matsumoto Bicyclic heterocyclic compound and use thereof
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
EP2455370A1 (en) 2009-07-17 2012-05-23 Shionogi&Co., Ltd. Pharmaceutical product containing lactam or benzene sulfonamide compound
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN112584832A (zh) 2018-06-14 2021-03-30 斯克里普斯研究学院 用于物质使用复发的非肌肉肌球蛋白ii抑制剂
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022061226A1 (en) * 2020-09-19 2022-03-24 Augusta University Research Institute, Inc. Compositions and methods for inhibiting trem-1
CN115340483A (zh) * 2022-08-31 2022-11-15 南京吉星生物技术开发有限公司 一种萘基吡咯啉二酮化合物及其制备方法与它的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
JPS5046697A (cg-RX-API-DMAC7.html) * 1973-08-20 1975-04-25
US5539126A (en) * 1994-04-20 1996-07-23 Bristol-Myers Squibb Company Method for preparing homochiral maleimide intermediates, via silylation techniques
DK0800519T3 (da) * 1994-12-22 2004-03-01 Ligand Pharm Inc Steroidreceptormodulatorforbindelser og fremgangsmåder
WO1997049709A1 (en) * 1996-06-27 1997-12-31 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP0979407A1 (en) * 1997-04-29 2000-02-16 The Salk Institute For Biological Studies Methods for identifying ligands for nuclear hormone receptors
US7101681B1 (en) * 1997-11-21 2006-09-05 Amgen, Inc. Nuclear hormone receptor drug screens
EP1214325B1 (en) * 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use

Similar Documents

Publication Publication Date Title
JP2004509895A5 (cg-RX-API-DMAC7.html)
KR100765670B1 (ko) 융합된 헤테로시클릭 숙신이미드 화합물 및 그의 유사체,핵 호르몬 수용체 기능의 조절제
ES2534392T3 (es) Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso
JP2007505877A5 (cg-RX-API-DMAC7.html)
RU2402553C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛ-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
AR040971A1 (es) Compuestos pirimido que tienen actividad antiproliferativa
CA2651363A1 (en) Triazolopyrazine derivatives useful as anti-cancer agents
JP2008526999A5 (cg-RX-API-DMAC7.html)
YU35603A (sh) Derivati benzodiazepina kao modulatori gaba a receptora
JP2007538092A5 (cg-RX-API-DMAC7.html)
JP2005518382A5 (cg-RX-API-DMAC7.html)
CA2737999A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP1340498A1 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
JP2003528096A5 (cg-RX-API-DMAC7.html)
CN1774253A (zh) 用环氧丙酯酮衍生物治疗顽固性肿瘤
MXPA06000191A (es) Combinacion de los inhibidores de src cinasa y agentes quimioterapeuticos para el tratamiento de enfermedades proliferativas.
RU2008110917A (ru) ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
JP2006512366A5 (cg-RX-API-DMAC7.html)
JP2009507788A5 (cg-RX-API-DMAC7.html)
JP2005521676A5 (cg-RX-API-DMAC7.html)
JP2006516626A5 (cg-RX-API-DMAC7.html)
RU2007116987A (ru) Новые соединения
RU2009101299A (ru) Трициклическое соединение и его фармацевтическое применение
RU2009128968A (ru) Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии
JP2009514801A5 (cg-RX-API-DMAC7.html)